文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病患者血压控制与降压药处方模式存在显著国际差异

Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease.
PubMed 文献 · Kidney Int · 2019-07-26

粗患病率显示血压≥140/90 mm Hg为28%至61%,≥130/80 mm Hg为54%至84%;调整后患病率比提示欧洲部分国家、印度和乌拉圭控制较差,北美和高收入亚洲国家较好。降压药处方模式国际差异显著,需进一步研究不同策略对患者结局的影响。

要点

  • 慢性肾脏病患者未控制高血压粗患病率国际差异大,血压≥140/90为28%至61%。
  • 调整后欧洲部分国家、印度和乌拉圭血压控制差于预期,北美和高收入亚洲国家较好。
  • 肾素-血管紧张素-醛固酮系统抑制剂是最常用降压药,处方率54%至91%。

核心结论

  • 慢性肾脏病患者血压控制和降压药处方模式存在显著国际异质性。
  • 研究涉及的混杂因素仅能解释国际差异的一部分。

研究设计与样本

  • 计算未控制血压的粗患病率及调整潜在混杂因素后的观察与预期患病率比。

主要发现

  • 血压≥140/90 mm Hg的粗患病率范围为28%至61%。
  • 血压≥130/80 mm Hg的粗患病率范围为54%至84%。
  • 调整后患病率比显示欧洲部分国家、印度和乌拉圭队列高血压控制差于预期,北美和高收入亚洲国家患者控制较好。
  • 北美和部分欧洲队列中超过30%的参与者被处方4类或以上降压药,其他地区较少见。
  • 肾素-血管紧张素-醛固酮系统抑制剂处方率为54%至91%,利尿剂为11%至79%,β受体阻滞剂为22%至70%,钙通道阻滞剂为27%至75%。

临床怎么用

  • 临床应关注慢性肾脏病患者的血压控制达标情况,尤其在高风险地区。
  • 处方降压药时需考虑国际差异背后的不同策略对患者结局的潜在影响。

局限性

  • 研究的混杂因素仅能解释国际差异的一部分。
  • 需要进一步研究不同降压策略对患者结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although blood pressure control is a major goal in chronic kidney disease, no worldwide overview of either its achievement or antihypertensive prescriptions is currently available. To evaluate this we compared crude prevalence of uncontrolled blood pressure among 17 cohort studies, including 34 602 individuals with estimated glomerular filtration rate under 60 ml/min/1.73 m2 and treated hypertension across four continents, and estimated observed to expected prevalence ratios, adjusted for potential confounders. Crude prevalence of blood pressure of 140/90 mm Hg or more varied from 28% to 61% and of blood pressure of 130/80 or more from 54% to 84%. Adjusted prevalence ratios indicated poorer hypertension control than expected in cohorts from European countries, India, and Uruguay, and better control in patients from North American and high-income Asian countries. Four antihypertensive drug classes or more were prescribed to more than 30% of participants in North American and some European cohorts, but this practice was less common elsewhere. Renin angiotensin-aldosterone system inhibitors were the most common antihypertensive drugs, prescribed for 54% to 91% of cohort participants. Differences for other drug classes were much stronger, ranging from 11% to 79% for diuretics, 22% to 70% for beta-blockers, and 27% to 75% for calcium-channel blockers. The confounders studied explain only a part of the international variation in blood pressure control among individuals with chronic kidney disease. Thus, considerable heterogeneity in prescription patterns worldwide calls for further investigation into the impact of different approaches on patient outcomes.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Alencar de Pinho N, Levin A, Fukagawa M, et al. Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. Kidney Int. 2019. PMID: 31358344. doi:10.1016/j.kint.2019.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。